Sigma Healthcare poaches Total Tools boss

Sigma Healthcare has poached an experienced executive to be its new chief financial officer.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Sigma Healthcare has appointed a new chief financial officer. 
  • The new hire has decades of experience, including at a high level with JB Hi-Fi. 
  • The company's shares traded higher on the news.
A senior pharmacist talks to a customer at the counter in a shop.

Image source: Getty Images

Chemist Warehouse owner Sigma Healthcare Limited (ASX: SIG) has poached the boss of Total Tools to be its new chief financial officer.

The $34.6 billion company, created in February from the merger of the ASX-listed Sigma and the privately held Chemist Warehouse Group, said on Tuesday that Total Tools' Richard Murray would join on October 13.

Richard has extensive ASX listed company experience spanning over 30 years. Most recently, he was the Chief Executive Officer of Total Tools, a Division of Metcash Limited. Previously, Richard was with Premier Investments Ltd where he was CEO Premier Retail, overseeing The Just Group's seven retail brands with around 1100 stores globally.

Prior to his time at Premier, Mr Murray held senior leadership positions with JB Hi-Fi Limited (ASX: JBH) for almost 20 years, Sigma said, joining ahead of that company's listing on the ASX and overseeing its ascension to be an S&P/ASX 100 Index (ASX: XTO) company.

Most notably, Richard was Chief Financial Officer for twelve years and Chief Executive Officer for seven years. During this period, Richard drove strong store and revenue growth, focused on cost management and financial reporting, and the acquisition and subsequent integration of The Good Guys business.

Sigma shares traded as high as $3.05 on the news of Mr Murray's appointment before moderating to be changing hands for $3.02, up 2.4 cents.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Premier Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »